Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal

Conclusions Apixaban is a cost-effective alternative to warfarin and dabigatran and is dominant over rivaroxaban in AF patients from the perspective of the Portuguese national healthcare system. These conclusions are based on indirect comparisons, but despite this limitation, the information is useful for healthcare decision-makers.
Source: Revista Portuguesa de Cardiologia - Category: Cardiology Source Type: research